Terms: = Breast cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Prognosis
14 results:
1. Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea.
Yun J; Song H; Kim SM; Kim S; Kwon SR; Lee YE; Jeong D; Park JH; Kwon S; Yun H; Lee DS
Hum Genomics; 2023 Feb; 17(1):13. PubMed ID: 36814285
[TBL] [Abstract] [Full Text] [Related]
2. FD-1050@NPs-cRGD: A novel NIR-II fluorophore for triple-negative breast cancer imaging.
Fan H; Wu W; Chen Z; Zhu Q; Sun X
Bioorg Med Chem Lett; 2023 Feb; 82():129153. PubMed ID: 36706843
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected breast cancers vs Interval breast cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract] [Full Text] [Related]
4. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract] [Full Text] [Related]
5. Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer.
Holah NS; Hemida AS
J Immunoassay Immunochem; 2020; 41(1):28-44. PubMed ID: 31631753
[TBL] [Abstract] [Full Text] [Related]
6. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Yamanouchi K; Kuba S; Eguchi S
Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptomic Profiling of MDA-MB-231 Cells Exposed to
Mazzio EA; Lewis CA; Soliman KFA
Cancer Genomics Proteomics; 2017; 14(6):409-425. PubMed ID: 29109091
[TBL] [Abstract] [Full Text] [Related]
9. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Denkert C; Loibl S; Kronenwett R; Budczies J; von Törne C; Nekljudova V; Darb-Esfahani S; Solbach C; Sinn BV; Petry C; Müller BM; Hilfrich J; Altmann G; Staebler A; Roth C; Ataseven B; Kirchner T; Dietel M; Untch M; von Minckwitz G
Ann Oncol; 2013 Mar; 24(3):632-9. PubMed ID: 23131391
[TBL] [Abstract] [Full Text] [Related]
10. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract] [Full Text] [Related]
11. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins.
Milde-Langosch K; Löning T; Bamberger AM
Breast Cancer Res Treat; 2003 May; 79(2):175-85. PubMed ID: 12825852
[TBL] [Abstract] [Full Text] [Related]
12. Progesterone receptor immunohistochemical quantitation compared with cytosolic assay: correlation with prognosis in breast cancer.
Lohmann C; Gibney E; Cotsonis G; Lawson D; Cohen C
Appl Immunohistochem Mol Morphol; 2001 Mar; 9(1):49-53. PubMed ID: 11277415
[TBL] [Abstract] [Full Text] [Related]
13. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Narita T; Funahashi H; Satoh Y; Takagi H
Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
[TBL] [Abstract] [Full Text] [Related]
14. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up.
Bosari S; Lee AK; Viale G; Heatley GJ; Coggi G
Virchows Arch A Pathol Anat Histopathol; 1992; 421(4):291-5. PubMed ID: 1413493
[TBL] [Abstract] [Full Text] [Related]
